EFM
CTMX icon

E Fund Management’s CytomX Therapeutics CTMX Stock Holding History

E Fund Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Buy
31,214
+1,067
+4% +$4.07K ﹤0.01% 471
2026
Q1 		$142K Buy
+30,147
New +$153K ﹤0.01% 462

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

E Fund Management's CTMX Position: Q2 2026 in Review

E Fund Management increased its CytomX Therapeutics (CTMX) stake by 3.5% in Q2 2026, buying an estimated $4.07K and bringing the position to 31,214 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #471.

E Fund Management first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $142K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • E Fund Management held 31,214 shares of CytomX Therapeutics worth $117K as of Q2 2026.
  • E Fund Management bought 1,067 CytomX Therapeutics shares in Q2 2026, an estimated $4.07K.
  • CytomX Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #471 holding.
  • E Fund Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's CytomX Therapeutics position peaked at $142K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.